Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models

FLT3 internal tandem duplication (FLT3-ITD) mutations account for approximately 25% of adult acute myeloid leukemia (AML) cases and are associated with poor prognosis. Venetoclax, a selective BCL-2 inhibitor, has limited monotherapy activity in relapsed/refractory AML with no responses observed in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mali, Raghuveer Singh, Zhang, Qi, DeFilippis, Rosa Anna, Cavazos, Antonio, Kuruvilla, Vinitha Mary, Raman, Jayant, Mody, Vidhi, Choo, Edna F., Dail, Monique, Shah, Neil P., Konopleva, Marina, Sampath, Deepak, Lasater, Elisabeth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017817/
https://www.ncbi.nlm.nih.gov/pubmed/32414851
http://dx.doi.org/10.3324/haematol.2019.244020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017817/
https://www.ncbi.nlm.nih.gov/pubmed/32414851
http://dx.doi.org/10.3324/haematol.2019.244020

Ejemplares similares